Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
LGND Ligand Pharmaceuticals Incorporated daily Stock Chart
LGND [NASD]
Ligand Pharmaceuticals Incorporated
Healthcare | Biotechnology | USA
statements
Index- P/E3.87 EPS (ttm)27.81 Insider Own3.70% Shs Outstand17.54M Perf Week-4.42%
Market Cap1.89B Forward P/E30.32 EPS next Y3.55 Insider Trans0.93% Shs Float15.42M Perf Month-2.49%
Income594.80M PEG- EPS next Q0.63 Inst Own- Short Float49.60% Perf Quarter20.20%
Sales152.90M P/S12.34 EPS this Y212.30% Inst Trans-6.20% Short Ratio19.71 Perf Half Y-5.29%
Book/sh45.32 P/B2.37 EPS next Y18.54% ROA36.40% Target Price196.20 Perf Year-33.66%
Cash/sh65.54 P/C1.64 EPS next 5Y-4.10% ROE67.30% 52W Range84.45 - 154.37 Perf YTD-20.72%
Dividend- P/FCF- EPS past 5Y69.60% ROI11.20% 52W High-32.03% Beta1.27
Dividend %- Quick Ratio33.00 Sales past 5Y38.70% Gross Margin91.90% 52W Low24.24% ATR3.82
Employees116 Current Ratio33.10 Sales Q/Q-45.70% Oper. Margin- RSI (14)44.26 Volatility2.83% 4.01%
OptionableYes Debt/Eq0.74 EPS Q/Q-129.00% Profit Margin- Rel Volume0.93 Prev Close107.58
ShortableYes LT Debt/Eq0.74 EarningsNov 05 AMC Payout0.00% Avg Volume388.20K Price104.92
Recom1.80 SMA20-3.06% SMA50-1.72% SMA200-4.89% Volume362,178 Change-2.47%
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Mar-11-16Initiated Sidoti Buy
Mar-03-16Initiated H.C. Wainwright Buy $146
Dec-18-15Reiterated ROTH Capital Buy $144 → $146
Nov-19-15Reiterated ROTH Capital Buy $138 → $144
Sep-30-15Reiterated ROTH Capital Buy $135 → $140
Jun-19-15Reiterated Cantor Fitzgerald Hold $86 → $93
Dec-05-19 11:31AM  Why Is Ligand (LGND) Up 5.3% Since Last Earnings Report? Zacks
Dec-02-19 08:30AM  Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi Business Wire
Nov-19-19 07:16AM  Edited Transcript of LGND earnings conference call or presentation 5-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 08:30AM  Ligand Pharmaceuticals Ranked in Deloittes 2019 Technology Fast 500 Business Wire
Nov-08-19 08:30AM  Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol Business Wire +7.06%
Nov-07-19 08:30AM  Ligand to Participate in the Stephens 2019 Nashville Investment Conference Business Wire
Nov-06-19 09:33AM  Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down Zacks -8.57%
Nov-05-19 06:15PM  Ligand Pharmaceuticals (LGND) Q3 Earnings Miss Estimates Zacks
04:02PM  Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals CNW Group
04:01PM  Ligand Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 10:32AM  Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-25-19 10:13AM  Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ? Insider Monkey
Oct-22-19 04:01PM  Ligand to Report Third Quarter 2019 Results on November 5th Business Wire
Oct-15-19 09:00AM  Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors Business Wire
Oct-10-19 10:08AM  Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares? Simply Wall St.
Oct-03-19 08:00AM  ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom CNW Group +5.03%
Sep-23-19 10:01AM  Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer GlobeNewswire
Sep-13-19 08:42AM  Ligand (LGND) Surges: Stock Moves 6.3% Higher Zacks
Sep-12-19 06:41AM  Ligand Pharmaceuticals approves new $500 million stock buyback program MarketWatch +6.26%
Aug-29-19 09:31AM  Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report? Zacks
09:00AM  Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference Business Wire
Aug-23-19 07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-14-19 06:15PM  3 Top Biotech Stocks to Buy in August Motley Fool
Aug-12-19 09:00AM  Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China Business Wire
Aug-03-19 08:51AM  Edited Transcript of LGND earnings conference call or presentation 30-Jul-19 1:00pm GMT Thomson Reuters StreetEvents
Jul-31-19 09:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $176,582 of Shares GuruFocus.com
10:44AM  Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat Zacks
Jul-30-19 06:09PM  Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript Motley Fool -11.38%
01:32PM  Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings Benzinga
09:25AM  Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates Zacks
08:00AM  Ligand Reports Second Quarter 2019 Financial Results Business Wire
Jul-23-19 04:15PM  Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company Business Wire
10:32AM  Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-17-19 01:49PM  Andrew Left's Citron Capital posted net return of 24.7% in 1st half of 2019 Reuters
Jul-16-19 11:19AM  Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP PR Newswire
Jul-15-19 09:00AM  Ligand to Report Second Quarter 2019 Results on July 30th Business Wire
Jul-12-19 07:36AM  Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value Simply Wall St.
Jul-10-19 09:00AM  Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol Business Wire
Jul-08-19 08:30AM  Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation PR Newswire
Jul-01-19 09:00AM  ZULRESSO (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligands Captisol® in its Formulation, Launched by Sage Therapeutics Business Wire
Jun-20-19 02:52PM  What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future? Simply Wall St.
Jun-13-19 09:36AM  Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks
Jun-12-19 09:00AM  Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target Business Wire
Jun-10-19 01:54PM  Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy? Insider Monkey
Jun-03-19 11:52AM  Should You Worry About Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Salary Level? Simply Wall St.
May-31-19 09:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $108,200 of Shares GuruFocus.com
May-20-19 09:04AM  Ligand Grants Preclinical Candidate Rights to UK-based Firm Zacks
May-17-19 09:00AM  Ligand Licenses VER250840 to Cumulus Oncology Business Wire
May-14-19 10:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $283,750 of Shares GuruFocus.com
May-10-19 12:21PM  A Closer Look At Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Impressive ROE Simply Wall St.
May-09-19 06:57AM  AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates Zacks
May-08-19 04:00PM  Mallinckrodt (MNK) Beats on Q1 Earnings & Sales, Raises View Zacks
May-07-19 09:42PM  Edited Transcript of LGND earnings conference call or presentation 2-May-19 8:30pm GMT Thomson Reuters StreetEvents
01:51PM  Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss Zacks
08:56AM  Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q1 Zacks
May-06-19 02:52PM  Novan adds more cash, now confident it can execute American City Business Journals
09:00AM  Novan Completes Funding Transaction with Ligand Pharmaceuticals GlobeNewswire
09:00AM  Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc. Business Wire
May-03-19 08:42AM  Ligand (LGND) Q1 Earnings & Sales Fall Y/Y, Stock Down Zacks
07:49AM  The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen Benzinga
May-02-19 09:56PM  Ligand Pharmaceuticals Incorporated (LGND) Q1 2019 Earnings Call Transcript Motley Fool
06:05PM  Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates Zacks
05:00PM  Ligand: 1Q Earnings Snapshot Associated Press
04:01PM  Ligand Reports First Quarter 2019 Financial Results Business Wire
09:00AM  Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol Business Wire
Apr-29-19 09:32AM  Is Ligand Pharmaceuticals Inc. (LGND) A Good Stock To Buy? Insider Monkey
Apr-25-19 10:34AM  Ligand Pharmaceuticals (LGND) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-24-19 05:57PM  Like Amazon, these stocks have 100% buy ratings from analysts MarketWatch
Apr-19-19 12:19PM  5 Top Biotech Stocks to Buy in 2019 Motley Fool
Apr-18-19 09:00AM  Ligand to Report First Quarter 2019 Results on May 2nd Business Wire
Apr-10-19 12:24PM  Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) A Financially Sound Company? Simply Wall St.
Mar-21-19 09:00AM  Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics ZULRESSO (brexanolone) Injection Business Wire
Mar-19-19 12:26PM  Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight Zacks
Mar-18-19 09:02AM  Rising P/E an Overlooked Criterion: 5 Top Stocks Zacks
Mar-15-19 03:15PM  Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares GuruFocus.com
09:30AM  LGND vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
Mar-13-19 09:11AM  Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals Zacks
Mar-12-19 04:01PM  Ligand to Participate in Four Upcoming Investor Conferences Business Wire
10:00AM  Ligand Provides Highlights from Todays Analyst Day Event Business Wire
09:42AM  4 High Earnings Yield Stocks to Strengthen Your Portfolio Zacks
Mar-11-19 10:00AM  Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment GlobeNewswire
Mar-09-19 09:31AM  Ligand (LGND) Down 9.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-07-19 11:22AM  Investors Who Bought Ligand Pharmaceuticals Shares Five Years Ago Are Now Up 46% Simply Wall St.
Mar-06-19 03:49PM  Here's Why Ligand Pharmaceuticals Is Having a Bad Day Motley Fool -11.68%
09:05AM  Ligand Sells Promacta Rights for $827M, Updates '19 View Zacks
Mar-05-19 04:01PM  Ligand Sells Promacta Assets and Royalty for $827 Million Business Wire
07:10AM  Detailed Research: Economic Perspectives on Twenty-First Century Fox, Acadia Healthcare, Targa Resources, WellCare Health Plans, Ligand Pharmaceuticals, and Duke Energy What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-04-19 10:00AM  Sermonix to Present Poster at ENDO 2019 on Lasofoxifenes Potent Anti-Tumor Activity in ESR1 Hormone-Resistant Breast Cancer GlobeNewswire
Feb-21-19 09:00AM  Reminder: Ligand to Host Analyst Day on March 12th in New York City Business Wire
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
Feb-11-19 05:15PM  Edited Transcript of LGND earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
Feb-08-19 10:00AM  AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates Zacks
08:03AM  Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View Zacks
Feb-07-19 09:57PM  Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:20PM  Ligand Pharmaceuticals (LGND) Q4 Earnings and Revenues Top Estimates Zacks
04:21PM  Ligand: 4Q Earnings Snapshot Associated Press
04:01PM  Ligand Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
09:00AM  Ligand Announces OmniAb® Partnership with Genagon Therapeutics Business Wire
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WPresident and COONov 12Option Exercise21.921,00121,942144,620Nov 13 04:07 PM
FOEHR MATTHEW WPresident and COOSep 05Option Exercise21.921,00522,030143,619Sep 05 07:24 PM
Aryeh JasonDirectorSep 03Buy87.0175065,25867,203Sep 04 07:30 PM
Korenberg Matthew EEVP,Finance & Strategy and CFOSep 03Buy86.1850043,09117,151Sep 03 07:34 PM
FOEHR MATTHEW WPresident and COOAug 12Option Exercise21.921,16325,493142,614Aug 13 01:45 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryAug 05Option Exercise67.721,09374,01347,172Aug 06 05:17 PM
Aryeh JasonDirectorAug 05Buy90.0174667,14666,453Aug 06 05:18 PM
Davis Todd CDirectorAug 02Buy93.591,00093,59449,474Aug 05 07:04 PM
Patel SunilDirectorAug 02Buy95.981,00095,98026,359Aug 05 06:56 PM
LAMATTINA JOHN LDirectorAug 01Option Exercise32.302,50080,75024,784Aug 05 07:00 PM
HIGGINS JOHN LChief Executive OfficerJul 31Buy95.451,850176,583146,749Jul 31 07:26 PM
Aryeh JasonDirectorJul 31Buy93.0075470,12265,707Jul 31 06:50 PM
Sabba Stephen LDirectorJul 31Sale94.454,091386,39523,600Aug 01 02:49 PM
Aryeh JasonDirectorJul 30Buy100.223,000300,66364,953Jul 31 06:50 PM
Aryeh JasonDirectorJul 29Buy106.0125026,50361,953Jul 31 06:50 PM
FOEHR MATTHEW WPresident and COOJun 11Option Exercise21.921,00422,008141,451Jun 12 06:50 PM
Aryeh JasonDirectorJun 11Buy107.0125026,75361,703Jun 12 06:51 PM
Aryeh JasonDirectorMay 31Buy108.5150054,25560,618May 31 06:27 PM
HIGGINS JOHN LChief Executive OfficerMay 31Buy108.201,000108,202144,899May 31 07:29 PM
Aryeh JasonDirectorMay 30Buy110.0125027,50360,118May 31 06:27 PM
Aryeh JasonDirectorMay 29Buy111.0125027,75359,868May 31 06:27 PM
Aryeh JasonDirectorMay 20Buy112.0125028,00359,618May 22 05:36 PM
KOZARICH JOHN WDirectorMay 14Option Exercise17.882,50044,70028,042May 14 07:56 PM
HIGGINS JOHN LChief Executive OfficerMay 14Buy113.502,500283,750143,899May 14 07:57 PM
Aryeh JasonDirectorMay 14Buy112.5125028,12859,368May 16 03:54 PM
KOZARICH JOHN WDirectorMay 14Sale112.922,500282,30025,542May 14 07:56 PM
FOEHR MATTHEW WPresident and COOMar 14Option Exercise9.9714,894148,493140,447Mar 15 02:00 PM
HIGGINS JOHN LChief Executive OfficerMar 13Buy114.292,500285,725141,399Mar 15 01:58 PM
Aryeh JasonDirectorMar 13Buy112.5120222,72751,594Mar 15 01:59 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryJan 10Option Exercise65.622,850187,02939,913Jan 14 09:17 AM
HIGGINS JOHN LChief Executive OfficerJan 10Option Exercise16.1433,790545,371119,209Jan 14 09:16 AM
Berkman Charles SSVP, Gen. Counsel & SecretaryDec 17Option Exercise21.923,40074,52837,063Dec 17 07:58 PM
FOEHR MATTHEW WPresident and COODec 12Option Exercise9.977,99979,750113,387Dec 12 05:32 PM
open in yahoo | open in reuters | open in google